Injection Techniques Questionnaire (ITQ) WorldWide Results Insulin Usage

Similar documents
Injection Techniques Questionnaire (ITQ) WorldWide Results Needle Gauge

Correct Site Rotation

Global EHS Resource Center

World Connections Committee (WCC) Report

Terms and Conditions. VISA Global Customer Assistance Services

Pharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.

WELLNESS COACHING. Wellness & Personal Fitness Solution Providers

Sperm donation Oocyte donation. Hong Kong þ Guideline þ þ Hungary þ þ þ þ Israel þ þ þ þ Italy þ þ þ. Germany þ þ þ þ Greece þ þ þ þ

Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE)

Country-wise and Item-wise Exports of Animal By Products Value Rs. Lakh Quantity in '000 Unit: Kgs Source: MoC Export Import Data Bank

Summary of Results for Laypersons

Main developments in past 24 hours

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?

EU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017

ESPEN Congress Geneva 2014 FOOD: THE FACTOR RESHAPING THE SIZE OF THE PLANET

- Network for Excellence in Health Innovation

Lessons learned from working with international injection technique guidelines

Country Length Discount Travel Period Anguilla All 20% off 08/24/11 12/15/11 Antigua All 20% off 08/24/11 12/15/11 Argentina All 20% off 08/24/11

Undetectable = Untransmittable. Mariah Wilberg Communications Specialist

CONNECTED HEALTH TRENDS

WELLNESS COACHING. Wellness & Personal Fitness Solution Providers NZ & Australia

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB

Enriched RWE study in the Nordics a case study

CND UNGASS FOLLOW UP

A Summary of Childhood Cancer Statistics in Australia,

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

Chemical compatibility of the Pall QPoint TM Docking Station - Tap Assembly with common surface disinfectants

Sponsor. Generic Drug Name. Trial Indication(s) Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Novartis.

Appendix F: Test-Curriculum Matching Analysis

Injection Technique (I.T.), Glycemic Variability, and Lipohypertrophy. Why I.T. All Matters

Tobacco: World Markets and Trade

Field of Post-M.D. Training

Current State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2

Louisville '19 Attachment #69

Allied Health: Sustainable Integrated Health Care for all Australians

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

MENTAL HEALTH CARE. OECD HCQI Expert meeting 17 th of May, Rie Fujisawa

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Recommended composition of influenza virus vaccines for use in the 2007 influenza season

Appendix F. The Test-Curriculum Matching Analysis Science TIMSS 2011 INTERNATIONAL RESULTS IN SCIENCE APPENDIX F 479

BioPlex 2200 Infectious Disease Panels

HPV Vaccines: Background and Current Status

Emily J. Hadgkiss, 1 George A. Jelinek, 1,2 Tracey J. Weiland, 1,3 Naresh G. Pereira, 4 Claudia H. Marck, 1 and Dania M.

Reza Fadayevatan Vida Alizad Ali Asgari

NobelDesign 1.3 Installation guide

THE CARE WE PROMISE FACTS AND FIGURES 2017

Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link System. Fully-Automated HbA 1c Testing

ETB Data. there was. compared

Global Measles and Rubella Update November 2018

Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link. Fully-Automated HbA 1c Testing

Global Measles and Rubella Update October 2018

The first and only fully-automated, multiplexed solution for Measles, Mumps, Rubella and Varicella-zoster virus antibody testing

Health Care Providers:

3.1 PHASE 2 OF THE GLOBAL PROJECT

Global Measles and Rubella Update. April 2018

ORBE Summary of Benefits

Immunohematology. IH-QC Modular System. Select. Combine. Control.

2010 Preventive Care Guidelines

Access to treatment and disease burden

THE GLOBAL HEALTH SECURITY AGENDA. We have to change our mindsets and start thinking about biological threats as the security threats that they are.

Drug resistance TB in People Living with HIV: research questions and priorities.

IMPLANTABLE MAGNETIC TRANSCUTANEOUS BONE CONDUCTION HEARING SYSTEM REIMBURSEMENT CODING GUIDE

IOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos. Jonathan Hughes IOSH Vice President

Performance against the USLP global nutrition targets in key countries 2017

NobelProcera Implant Bar Overdenture EXPERIENCE THE NEW WORLD OF CAD/CAM DENTISTRY

Summary of Results for Laypersons

EASY-Care program in Iran. Dr Reza Fadayevatan, MD, MPH, PhD Head of Ageing Department, The University of Social welfare and Rehabilitation Sciences

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

of the Bone and Joint Decade The Global Challenge of Fragility Fractures and the Role of Fragility fracture Network

EMBARGOED UNTIL 22 JUNE PM CEST (GMT+2)

ISAPS International Survey on Aesthetic/Cosmetic Procedures Performed in 2010

World Health Organization Organisation mondiale de la Santé

Global Polybutylene Terephthalate (PBT) Market Study ( )

CYCLOTRONS WORLD MARKET REPORT & DIRECTORY EDITION TOC and Summary USED IN NUCLEAR MEDICINE MARKET DATA, COMPANIES PROFILES.

What is the extent of gender bias in bioinformatics?

2017 GLOBAL PAIN INDEX (GPI) Better for Everyone

SUBMISSION FOR THE RECLASSIFICATION OF SODIUM PICOSULPHATE FROM PRESCRIPTION MEDICINE TO PHARMACY MEDICINE

Infectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

The Global Summit of Women 2009 Santiago, Chile May 14-16

Global Terephthalic Acid (PTA) Market Study ( )

Insight Growth Balance STATISTICS pigmeat

Proton Therapy Market Outlook - Global Analysis

Alcohol Under 21 years old. Rory M Doyle, M.Sc Office of the Chief Medical Examiner Washington, DC

Improving Food Process Control Using the

Urgent Medical Device Correction

For personal use only

The health economic landscape of cancer in Europe

o Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH Publishing Date: July, 2017

EUROPEAN AEROSOL PRODUCTION

Population- based cancer survival estimates

Ferrari R, Fox K, Bertrand M, Mourad J.J, Akkerhuis KM, Van Vark L, Boersma E.

Monitoring EU Agri-Food Trade: Development until February 2018

PROMOTION AND PROTECTION OF ALL HUMAN RIGHTS, CIVIL, POLITICAL, ECONOMIC, SOCIAL AND CULTURAL RIGHTS, INCLUDING THE RIGHT TO DEVELOPMENT

High risk groups and disease markers. Professor Bruce Duncan Federal University of Rio Grande do Sul

Pandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva

What was the study about?

Summary of Results for Laypersons

Transcription:

Injection Techniques Questionnaire (ITQ) WorldWide Results 2014-2015 Insulin Usage

BACKGROUND

Lipohypertrophy in Diabetes or How much does a lipo cost? Dr. Treichel, Magdeburg Studies * have shown that the individual dose of insulin increases significantly when insulin is injected into lipohypertrophic tissue in order to achieve satisfying results for diabetes control. (*Franzen I, J. Ludvigsson, Linköping 1997 Specific InstructionsGave Reduction of Lipomas and Improved Metabolic Control in Diabetic Children, Diabetologia Vol 40, Supplement 1: A615 (1997)

Blutzucker mmol/l Results Intra-day variations of BG values were reduced. BG values generally went down to the proposed range. The individual daily insulin dose needed had to be reduced significantly. 18 16 14 12 10 8 6 4 2 0 7 9 12 15 18 22 3 1. Tag 14. Tag

Cost of Therapy Patient A (per year) prior to IT training Basal Humalog Pen Needles Sum Co- Payment 2.005 1.499 45 3.550 275 after IT training 573 551 498 1.622 128 difference (savings) 1.432 948 (453 ) 1.928 147

LH and Total Insulin Dose Lipohypertrophy Dose category Yes No Total Dose (mean IU/day) 56 41 Total Dose DM 1 50 42 Total Dose DM 2 62 41

Health Economic Costs This 15 IU difference multiplied over the number of daily injections into LH Assuming a cost of 0.0243 euros/iu Total annual cost to the Spanish health care system of over 122 million euros.

Cost of Additional Insulin Attributable to Injecting into LH PATIENTS INJECTING NUMBER OF TOTAL ADDITIONAL IU TOTAL ADDITIONAL IU ANNUAL FINANCIAL INSULIN in SPAIN ADDITIONAL IU PER DAY CONSUMED PER DAY CONSUMED PER YEAR IMPACT EURO* DM 1 139,500 8 1,116,000 407,340,000 9,474,728 DM 2 634,000 21 13,314,000 4,859,610,000 113,034,529 TOTAL 773,500 15 14,430,000 5,266,950,000 122,509,257 *assumes an average cost of 1 IU insulin in Spain of 0.02326 euros

COMPARATIVE STATISTICS: DEMOGRAPHICS

Is TDD related to DM type? TDD Mean SD N T1DM 48 25 2512 DM type T2DM 49 35 5030 GDM 22 23 81

TDD by Country in IU(1) Country Mean SD N USA 39 41 304 Canada 69 52 302 Russia 45 25 109 South Africa 53 33 149 Netherlands 70 38 75 Belgium 55 32 146 France 59 35 234 Spain 51 26 198 Italy 46 24 337 Switzerland 51 46 71 Austria 42 24 113

TDD by Country in IU (2) Country Mean SD N UK 63 41 409 Denmark 56 24 14 Sweden 59 31 102 Poland 44 20 101 Germany 57 33 447 Perú 22 10 24 Mexico 39 23 134 Argentina 45 20 73 Brazil 45 30 242 Chile 62 29 20 Colombia 37 19 45

TDD by Country in IU (3) Country Mean SD N Venezuela 35 16 25 Malaysia 53 24 50 Australia 63 36 81 Indonesia 27 19 124 Philippines 43 26 70 Singapore 44 15 23 S. Korea 41 23 179 China 32 16 491 Turkey 54 29 1251 India 36 23 982 Ireland 59 21 36

TDD by Country in IU (4) Country Mean SD N Finland 59 34 92 Czech Republic 57 32 126 Nicaragua 26 11 16 Taïwan 44 41 92 Saudi Arabia 41 26 410 United Arab Emirates 50 32 59 TOTAL 48 32 7756

COMPARATIVE STATISTICS: ASSOCIATIONS

Is Needle Length associated with total daily dose (TDD) of insulin? Needle Length Mean TDD N Std. Deviation 4 44.9 2031 31.6 5 47.6 1454 31.6 6 47.0 1466 29.6 8 54.0 1993 33.6 Total 48.5 6944 32.0 TDD less with 4, p < 0.000

What could explain this? 4mm used more frequently in younger patients and T1DM, both of whom use lower doses LH rates are lower with 4mm needles (for various reasons, not necessarily causative) and insulin use in LH- subjects are lower 4mm used more frequently in intensively treated patients (T1DM and T2DM), who use less insulin overall

What is the association between pain and TDD? PAIN Mean TDD N SD Δ = 4.9 IU Yes 51.0 3569 33.2 No 46.1 3484 31.3 Total 48.6 7053 32.3 p <0.000

Is TDD associated with Device? Mean Std. Deviation N Syringe 41 27 1028 Pen 49 32 6027 Other (pump) 42 21 110 Pen + Syringe 57 37 206 p <0.000

Is TDD associated with site of injection? TDD Mean SD N Abdomen alone 47 34 2029 Thigh alone 36 28 250 Arm alone 41 27 174 Site of Injection Abdomen/Thigh 51 33 1549 Abdomen/Arm 48 34 490 Thigh/Arm 48 26 306 Abd/Thigh/Arm 53 29 1281 All 4 46 27 646

Is TDD related to Leakage from Site? Leakage from Site Mean TDD SD N Yes 51 32 2819 Δ = 5 IU No 46 32 4777 Total 48 32 7596 p <0.000

Is TDD related to Reconstituting Cloudy Insulin? Reconstitute Mean TDD SD N Yes 46 28 2879 Δ = 3 IU No 49 34 1161 Total 47 30 4040 p = 0.026

Is TDD related to Skipping Injections? Skip Injections Mean TDD SD N Yes 50 31 3699 Δ = 4 IU No 46 32 3938 Total 48 32 7637 p <0.000

Is TDD related to Hyperglycemia? Hypers Mean TDD SD N Yes 53 33 3728 Δ = 10 IU No 43 30 3753 Total 48 32 7481 p <0.000

Is TDD related to Hypoglycemia? Hypos Mean TDD SD N Yes 52 32 4339 Δ = 9 IU No 43 31 3288 Total 48 32 7627 p <0.000

COMPARATIVE STATISTICS: OUTCOMES

What is the association between LH and the total daily dose of insulin (TDD)? LH Mean TDD N SD Yes 55.2 2192 33.0 No 45.1 4889 31.5 Total 48.2 7081 32.3 Δ = 10.2 IU Δ = 5.4 IU T1DM LH Mean TDD N SD Yes 51.2 1007 25.9 No 45.9 1286 24.5 Total 48.2 2293 25.3 T2DM LH Mean TDD N SD Yes 58.8 1159 38.0 No 45.2 3457 33.6 Total 48.6 4616 35.2 Δ = 13.5 IU p for all <0.000

What is the association between Injecting into LH and TDD? Inject into LH Mean TDD N SD Yes 56.1 1644 33.2 Δ = 9.0 IU No 47.1 2064 32.2 Total 51.1 3708 32.9 p <0.000

What is the association between LH and the TDD by Insulin type? Rapid Analogues LH Mean TDD N SD Yes 34.4 928 22.0 No 29.9 884 21.6 Total 32.2 1812 21.9 Δ = 4.5 IU Basal Analogues LH Mean TDD N SD Yes 28.7 1149 19.0 No 27.2 1228 22.0 Total 27.9 2377 20.6 Δ = 1.5 IU Premixes LH Mean TDD N SD Yes 49.9 319 30.2 No 40.0 479 22.9 Total 44.0 798 26.5 Δ = 9.8 IU p for all <0.000

Findings Insulin Consumption: Strong association between the presence of LH and the total daily dose (TDD) of insulin, with over 10 IU of insulin on average being consumed in the LH+ population vs LH-. In T2DM patients, this average TDD difference is 13.5 IU. In T1DM patients, the average TDD difference is 5.4 IU. 31

Findings Insulin Consumption: These differences were seen for different types of insulin: fast-acting analogue (mean of 4.4 IU more), basal analogue (mean of 1.5 IU more) and premix (mean of 9.8 IU more). 32

Findings Insulin Consumption: All currently used families of insulins are associated with the risk of LH. It is difficult to determine if any one type of insulin has higher risks. Even newer analogues show a prevalence of LH in double digits 33

Is TDD related to Correct Rotation? Correct Rotation Mean TDD SD N Yes 47 31 5220 Δ = 4 IU No 51 33 2164 Total 48 32 7384 p <0.000

Conclusions The average TDD is approximately the same between T1DM and T2DM (48-49 IU), with greater variability of dosage in patients with T2DM. There is huge variability in mean TDD and SD country to country. Lower TDD are associated with use of 4 mm needles, syringe use, use of limbs as sole injection sites and correct rotation of injections. Higher TDD are associated with leakage from the site, failing to reconstitute cloudy insulin, skipping injections, hypo- and hyperglycemia, injection pain, the presence of LH and injecting into LH.